2020年8月18日,

曾就讀醫學關閉48美元融資,名字新CEO曾就讀醫學關閉48美元融資,名字新任首席執行官馬特•布羅考建造ENT企業有長牙的動物醫學,Spirox,聖猿醫療、Stryker Acclarent,強生,史密斯+侄子。基於平台的技術提供持久的解決方案對鼻氣道阻塞和慢性鼻炎。私營醫療設備公司GlobeNewswire08.17.20 Aerin醫療專注於非侵入性程序治療鼻氣道條件,宣布關閉4800萬美元的股權融資。新投資者,資本OrbiMed圓與參與和現有投資者KCK組。所得資金將用於加速商業增長,支持新的臨床研究,開發新產品來更好地服務耳鼻喉科專家(耳朵、鼻子和喉嚨醫生或“樹人”)和他們的病人。作為投資的一部分,資本的創始人和合夥人瑞安Drant將加入Aerin董事會。曾為樹人提供tissue-sparing解決方案治療鼻腔疾病的改善病人的生活質量。ENT醫生使用公司的前進和RhinAer平台技術治療病人患有慢性鼻炎、鼻氣道阻塞和respectively-prevalent會使身體狀況日益衰弱的疾病,影響到數以百萬計的人每年在美國。該公司還宣布任命經驗豐富的醫療器械行政總裁兼首席執行官馬特•布羅考。他加入一個經驗豐富的管理團隊,致力於ENT專業。 Brokaw has a long record of commercial leadership, building successful ENT businesses at companies including Tusker Medical, Spirox, Entellus Medical, Stryker, Acclarent, Johnson & Johnson, and Smith+Nephew. “Aerin is primed for its next phase of growth, propelled by non-invasive treatments embraced by patients, and in-office procedure options that are increasingly important to the ENT specialty,” said Brokaw. “I’m tremendously excited to join the team at this critical period, and I look forward to working in close partnership with the otolaryngology community and this experienced group of healthcare investors.” Karen Long, Managing Director at KCK and Chairman of Aerin’s Board of Directors said, “We’re thrilled to add Matt’s leadership and operating experience to Aerin along with the business-scaling expertise and long-term capital partnership of Questa and OrbiMed. With these partners and Matt at the helm, we have all the pieces in place to continue building a strong, sustainable growth company.” Related Breaking News U.S. Food and Drug Administration 08.17.20 Purdue University 08.14.20 ASTM International 08.14.20 Business Wire 08.14.20 Business Wire 08.14.20 Philips 08.14.20 Business Wire 08.14.20 Business Wire 08.14.20 Sheba Medical Center 08.13.20 Business Wire 08.13.20 Business Wire 08.13.20 Business Wire 08.13.20 GlobalData 08.13.20 PR Newswire 08.13.20 Business Wire 08.12.20